Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthr… Read more
Tibet Rhodiola Pharmaceutical Holding Co (600211) - Total Assets
Latest total assets as of September 2025: CN¥5.82 Billion CNY
Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) holds total assets worth CN¥5.82 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tibet Rhodiola Pharmaceutical Holding Co - Total Assets Trend (1996–2024)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tibet Rhodiola Pharmaceutical Holding Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Tibet Rhodiola Pharmaceutical Holding Co's total assets of CN¥5.82 Billion consist of 75.2% current assets and 24.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 34.7% |
| Accounts Receivable | CN¥744.67 Million | 15.7% |
| Inventory | CN¥134.19 Million | 2.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥185.43 Million | 3.9% |
| Goodwill | CN¥8.88 Million | 0.2% |
Asset Composition Trend (1996–2024)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Rhodiola Pharmaceutical Holding Co's current assets represent 75.2% of total assets in 2024, an increase from 48.4% in 1996.
- Cash Position: Cash and equivalents constituted 34.7% of total assets in 2024, up from 5.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 15.7% of total assets.
Tibet Rhodiola Pharmaceutical Holding Co Competitors by Total Assets
Key competitors of Tibet Rhodiola Pharmaceutical Holding Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Tibet Rhodiola Pharmaceutical Holding Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Tibet Rhodiola Pharmaceutical Holding Co generates 0.59x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Tibet Rhodiola Pharmaceutical Holding Co generates $ 22.14 in net profit.
Tibet Rhodiola Pharmaceutical Holding Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 3.58 | 4.06 |
| Quick Ratio | 2.89 | 3.44 | 3.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.77 Billion | CN¥ 2.52 Billion | CN¥ 1.02 Billion |
Tibet Rhodiola Pharmaceutical Holding Co - Advanced Valuation Insights
This section examines the relationship between Tibet Rhodiola Pharmaceutical Holding Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.82 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | CN¥4.75 Billion |
| Market Capitalization | $761.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Rhodiola Pharmaceutical Holding Co's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tibet Rhodiola Pharmaceutical Holding Co's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tibet Rhodiola Pharmaceutical Holding Co (1996–2024)
The table below shows the annual total assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.75 Billion | +3.49% |
| 2023-12-31 | CN¥4.59 Billion | +11.90% |
| 2022-12-31 | CN¥4.10 Billion | +7.80% |
| 2021-12-31 | CN¥3.80 Billion | +29.15% |
| 2020-12-31 | CN¥2.94 Billion | +6.40% |
| 2019-12-31 | CN¥2.77 Billion | +9.29% |
| 2018-12-31 | CN¥2.53 Billion | +8.67% |
| 2017-12-31 | CN¥2.33 Billion | +1.72% |
| 2016-12-31 | CN¥2.29 Billion | +224.31% |
| 2015-12-31 | CN¥706.33 Million | -32.50% |
| 2014-12-31 | CN¥1.05 Billion | -8.00% |
| 2013-12-31 | CN¥1.14 Billion | +34.59% |
| 2012-12-31 | CN¥845.15 Million | +7.27% |
| 2011-12-31 | CN¥787.86 Million | +7.12% |
| 2010-12-31 | CN¥735.47 Million | -1.11% |
| 2009-12-31 | CN¥743.70 Million | -10.36% |
| 2008-12-31 | CN¥829.66 Million | -0.28% |
| 2007-12-31 | CN¥831.96 Million | -4.03% |
| 2006-12-31 | CN¥866.90 Million | +5.64% |
| 2005-12-31 | CN¥820.62 Million | +5.58% |
| 2004-12-31 | CN¥777.25 Million | +3.04% |
| 2003-12-31 | CN¥754.36 Million | +2.90% |
| 2002-12-31 | CN¥733.08 Million | +20.51% |
| 2001-12-31 | CN¥608.33 Million | +15.13% |
| 2000-12-31 | CN¥528.36 Million | +21.06% |
| 1999-12-31 | CN¥436.44 Million | +152.78% |
| 1998-12-31 | CN¥172.66 Million | +44.29% |
| 1997-12-31 | CN¥119.66 Million | +153.66% |
| 1996-12-31 | CN¥47.18 Million | -- |